西格列汀治疗老年2型糖尿病药物的临床研究资料.docVIP

西格列汀 维格列汀治疗老年2型糖尿病药物的临床研究 【摘要】 目的：比较分析维格列汀及阿卡波糖在治疗老年糖尿病中的有效性和安全性。方法：选取我院治疗的老年糖尿病患者82例。随机分为维格列汀治疗组和阿卡波糖治疗组各41例。比较两组治疗前后的BMI、空腹血糖（fasting plasma glucose，FPG）、餐后两小时血糖（2 - hr plasma glucose ，2hPG）、糖化血红蛋白（glycosylated hemoglobin, HbA1c)等指标。结果：两组老年患者组内和组间的BMI指数比较，均无显著性差异(P0.05)。两组患者的FPG值组内比较具有显著性差异(P0.05)，组间比较不具有显著性差异(P0.05)。两组患者的2hPG值和HbA1c含量组内及组间比较均具有显著性差异(P0.05)。组间血糖参数降幅比较，FPG不具有显著性差异(P0.05)，2hPG及HbA1c均具显著性差异(P0.05)。两组患者的不良反应发生率分别为7.32%和24.39%（P0.05）。结论：维格列汀和阿卡波糖均可有效的治疗老年患者的糖尿病。但在治疗过程中，维格列汀可表现出更好的改善血糖参数的功能，且可明显降低不良反应发生率，是值得临床推广的治疗糖尿病的药物。 [关键词]维格列汀；阿卡波糖；糖尿病； The efficacy and safety of the drugs for the old diabetes patients [Abstract] Objective To contrast the efficacy and safety of the vildagliptin and acarbose in the treatment of diabetes of old patients. Methods The 82 patients who had the diabetes were chose from the hospital. The old patients were randomly distributed into the vildagliptin treatment group and the acarbose treatment group, which group had the 41 cases. The clinical efficacy were executed the comparison and analysis. Results The old patients BMI index within the group and between groups didn’t perfromed the significant difference (P0.05). Before and after treatment, comparing the FPG within the group had the statistical significance(P0.05).The FPG between the vildagliptin treatment group and the acarbose treatment group exhibited no significant difference (P0.05). As far as the 2hPG and the HbA1c levels of the two groups, there were significant differences (P0.05) Whether the within or the between. The drop of the FPG has no significant difference (P0.05). And ones for the 2hPG and HbA1c were a significant difference (P0.05). The unwelcome reaction incidence in the vildagliptin group and the acarbose group were were 7.32% and 24.39%, respectively, of which χ2 was 4.4794 revealed the significant difference. Conclusion The Vildagliptin and acarbose for the diabetes possess the good effect. While the vildagliptin can improve more obviously the glycemic